Skip to content
MXCTMaxcyte, Inc.

Earnings

When Maxcyte, Inc. reports, what it reported each quarter, and how the stock took the results.

27 quarters. Mar 31, 2020 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 23, after the close

Tue, Mar 23, 2027in 125 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 8 – 26

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$16.86M
Revenue, change from a year earlier: Q2 2026 −15.2%, Q4 2025 −25.0%, Q3 2025 −18.0%, Q2 2025 n/m
Net income
-$9.60M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q2 2026$4.94M−15.2% vs Q2 2025

Latest results

  1. Q3 2026Nov 9, 2026, after the closeThe release11.2%by the close of Nov 10
    Revenue
    —
    —
    Net income
    -$4.76M
    N/M
    EPS
    -$0.05
    N/M
  2. Q2 2026Aug 12, 2026, after the closeThe release+10.7%by the close of Aug 13
    Revenue
    $4.94M
    −15.2%
    Net income
    -$8.87M
    N/M
    EPS
    -$0.08
    N/M
  3. Q1 2026May 12, 2026, after the closeThe release+24.4%by the close of May 13
    Revenue
    —
    —
    Net income
    -$4.75M
    N/M
    EPS
    -$0.04
    N/M
  4. Q4 2025Mar 24, 2026, after the closeThe release6.8%by the close of Mar 25
    Revenue
    $16.86M
    −25.0%
    Net income
    -$9.60M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 9, 2026 · after-hoursNov 10, 202641 d10-Q——-$0.0511.2%
Q2 2026Jun 30, 2026Aug 12, 2026 · after-hoursAug 13, 202644 d10-Q$4.94M−15.2%-$0.08+10.7%
Q1 2026Mar 31, 2026May 12, 2026 · after-hoursMay 13, 202643 d10-Q——-$0.04+24.4%
FY 2025
Q4 2025derivedDec 31, 2025Mar 24, 2026 · after-hoursMar 25, 202684 d10-K$16.86M−25.0%—6.8%
Q3 2025Sep 30, 2025Nov 12, 2025 · after-hoursNov 13, 202544 d10-Q$4.60M−18.0%-$0.124.4%
Q2 2025Jun 30, 2025Aug 6, 2025 · after-hoursAug 6, 202537 d10-Q$5.82M—-$0.1230.6%
Q1 2025Mar 31, 2025May 7, 2025 · after-hoursMay 8, 202538 d10-Q——-$0.1011.7%
FY 2024
Q4 2024derivedDec 31, 2024Mar 11, 2025 · after-hoursMar 11, 202570 d10-K$22.47M——8.4%
Q3 2024Sep 30, 2024Nov 6, 2024 · after-hoursNov 6, 202437 d10-Q$5.61M—-$0.1110.8%
Q2 2024Jun 30, 2024Aug 6, 2024 · after-hoursAug 6, 202437 d10-Q——-$0.094.3%
Q1 2024Mar 31, 2024May 7, 2024 · after-hoursMay 7, 202437 d10-Q———+25.5%
Earlier years, FY 2020 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 10, 2026125236
10-QAug 13, 2026095971
10-QMay 13, 2026060290
10-KMar 25, 2026034557
10-QNov 13, 2025111396
10-QAug 6, 2025010554
10-QMay 8, 2025007005
10-KMar 11, 2025002721
10-QNov 6, 2024014662
10-QAug 6, 2024011120

Provenance

ProvenanceData status and checks

Maxcyte, Inc. · CIK 1287098 · Engraved from SEC EDGAR